1. Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells.
- Author
-
Duinkerken S, Li RE, van Haften FJ, de Gruijl TD, Chiodo F, Schetters STT, and van Kooyk Y
- Subjects
- Animals, Humans, Cancer Vaccines chemistry, Cancer Vaccines immunology, Dendritic Cells immunology, Engineering, Polysaccharides chemistry, Polysaccharides immunology, Skin immunology
- Abstract
Dendritic cell (DC)-targeting vaccines show great promise in increasing antitumor immunity. Glycan-engineered vaccines facilitate both DC targeting and increased uptake by DCs for processing and presentation to CD4
+ and CD8+ T cells to induce tumor-specific T-cell responses. However, the complexity of various DC subsets in skin tissues, expressing different glycan-binding receptors that can mediate vaccine uptake or drainage of vaccines via lymphatics directly to the lymph node-resident DCs, complicates the success of vaccines. Moreover, the influx of inflammatory immune cells to the site of vaccination, such as monocytes that differentiate to DCs and coexpress glycan-binding receptors, may contribute to the strength of DC-targeting glycovaccines for future clinical use., (Copyright © 2019. Published by Elsevier Ltd.)- Published
- 2019
- Full Text
- View/download PDF